LILRB1-directed CAR-T cells for the treatment of hematological malignancies
Por:
Marhelava, K, Fidyt, K, Pepek, M, Krawczyk, M, Forcados, C, Malinowska, A, Swiderska, B, Fernandez-Fuentes, N, Czerwik, N, Baranowska, I, Krzywdzinska, A, Sedek, L, Slota, L, Perkowski, B, Villatoro, A, Leray, T, Lech-Maranda, E, Menendez, P, Inderberg, EM, Wälchli, S, Winiarska, M and Firczuk, M
Publicada:
1 jun 2025
Ahead of Print:
1 abr 2025
Resumen:
CD19 CAR-T cells have established a new standard for relapsed/refractory B-cell malignancies. However, the treatment fails in 50% of patients, often due to CD19 antigen loss. Alternative immunotherapies targeting other antigens are being tested but show limited efficacy, especially in cases of lineage switching or loss of B-cell phenotype, highlighting the need for novel targets. Herein, we identified leukocyte-immunoglobulin-like-receptor-B1 (LILRB1, CD85j) as a novel target for CAR-T cells through cell surface proteomics on patient-derived samples of high-risk B-cell acute lymphoblastic leukemia (B-ALL). LILRB1, an immune inhibitory receptor, is normally expressed only on monocytes and B-cells. We observed stable LILRB1 expression in B-ALL and B-cell non-Hodgkin lymphoma (B-NHL), even after CD20/CD19-based immunotherapies. LILRB1 CAR-T cells showed antigen-specific antitumor activity in vitro against B-ALL/B-NHL cells, including those resistant to CD19 CAR-T-cells, and in vivo in B-ALL xenografts. Additionally, we identified LILRB1 in monocytic acute myeloid leukemia (AML) and demonstrated LILRB1 CAR-T cell cytotoxicity against AML cell lines in vitro and in vivo. These findings establish LILRB1 as a novel target for cancer immunotherapy and show evidence for the preclinical efficacy of LILRB1 CAR-T cells against haematological malignancies, including cases resistant to previous lines of immunotherapy, thus holding promise for further clinical development.
Filiaciones:
Marhelava, K:
Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland
Med Univ Warsaw, Dept Immunol, Warsaw, Poland
:
Med Univ Warsaw, Dept Immunol, Warsaw, Poland
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Pepek, M:
Med Univ Warsaw, Dept Immunol, Warsaw, Poland
Krawczyk, M:
Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland
Med Univ Warsaw, Dept Immunol, Warsaw, Poland
Polish Acad Sci, Mossakowski Med Res Inst, Ctr Postgrad Med Educ, Doctoral Sch Translat Med, Warsaw, Poland
Forcados, C:
Oslo Univ Hosp, Dept Oncol, Translat Res Unit, Sect Cellular Therapy, Oslo, Norway
Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway
Malinowska, A:
Polish Acad Sci, Inst Biochem & Biophys, Mass Spectrometry Lab, Warsaw, Poland
Swiderska, B:
Polish Acad Sci, Inst Biochem & Biophys, Mass Spectrometry Lab, Warsaw, Poland
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Czerwik, N:
Med Univ Warsaw, Dept Immunol, Warsaw, Poland
Baranowska, I:
Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland
Krzywdzinska, A:
Inst Hematol & Transfus Med, Lab Immunophenotyping, Warsaw, Poland
Sedek, L:
Med Univ Silesia, Dept Microbiol & Immunol, Zabrze, Poland
Slota, L:
Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland
Perkowski, B:
Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland
Villatoro, A:
Oslo Univ Hosp, Dept Oncol, Translat Res Unit, Sect Cellular Therapy, Oslo, Norway
Leray, T:
Oslo Univ Hosp, Dept Oncol, Translat Res Unit, Sect Cellular Therapy, Oslo, Norway
Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway
Lech-Maranda, E:
Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland
:
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Oncol, Madrid, Spain
Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
Univ Barcelona, Sch Med, Dept Biomed, Barcelona, Spain
Inst Recerca Hosp, St Joan de Deu Pediat Canc Ctr Barcelona SJD PCCB, Barcelona, Spain
Inderberg, EM:
Oslo Univ Hosp, Dept Oncol, Translat Res Unit, Sect Cellular Therapy, Oslo, Norway
Winiarska, M:
Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland
Med Univ Warsaw, Dept Immunol, Warsaw, Poland
Firczuk, M:
Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, Warsaw, Poland
Med Univ Warsaw, Dept Immunol, Warsaw, Poland
Green Accepted, Green Submitted, hybrid
|